Arcutis Q2 product revenue $81.5M (+164% YoY); ZORYVE foam approved for scalp/body psoriasis

Arcutis Biotherapeutics, Inc.

2025-Q2 EPS reported -$0.32 revenue$147,350,000

Net product revenue $81.5M vs $30.9M YoY, driven by ZORYVE portfolio demand across four approved indications.
Net loss narrowed to $15.9M ($0.13/sh) from $52.3M ($0.42/sh) YoY; cash $191.1M as of June 30.
ZORYVE foam 0.3% approved in May 2025 for scalp/body psoriasis; sales commenced in June.
PDUFA date Oct 13, 2025 for ZORYVE cream 0.05% in children 2–5 with atopic dermatitis.
IND submitted for ARQ-234 (CD200R agonist); halted ARQ-255 (alopecia areata) program.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.